Compare Neurocrine Biosciences Inc (NBIX) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Neurocrine Biosciences Inc trades at $155.85 (market cap $15.77B), while Norwegian Cruise Line Holdings Ltd trades at $14.88 (market cap $6.82B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.3× Norwegian Cruise Line Holdings Ltd's market cap, and Neurocrine Biosciences Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| NBIX | NCLH | |
|---|---|---|
Market Cap | $15.77B | $6.82B |
Sector | Health | Consumer Cyclical |
52-Week High | $185.50 | $26.94 |
52-Week Low | $123.10 | $14.79 |
Enterprise Value | $15.78B | $21.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% on the day, with a bearish technical signal from moving averages. The stock shows strong fundamentals, including a 20.91% net income margin and robust revenue growth, with Q1 2026 EPS beating expectations. Recent news highlights institutional buying and pipeline progress, but safety concerns for Vykat XR have caused volatility.
The outlook is positive given analyst consensus of $207.07 price target and 86% buy ratings, supported by Ingrezza's growth and new drug launches. Key risks include drug safety issues, competitive pressures, and execution challenges in expanding the portfolio, which could impact shareholder returns amid current bearish technical trends.
Norwegian Cruise Line Holdings (NCLH) trades at $15.39, down 1.16% with bearish technical signals but attractive valuation metrics including a P/E of 9.33 and P/S of 0.74. The company has beaten earnings estimates for three consecutive quarters, though Q3 2026 faces a higher bar at $0.89 EPS. Recent news highlights fuel cost pressures from rising oil prices, contributing to the stock's recent decline despite positive operational developments like new waterpark openings and fleet expansion.
NCLH presents a value opportunity with strong profitability metrics (36.73% ROE) and analyst consensus price target of $20.25 (32% upside), but faces significant risks from fuel cost volatility, high leverage (debt-to-asset ratio 64.79%), and competitive pressure. The company's turnaround plan focusing on cost controls and fleet optimization must overcome macroeconomic headwinds to drive sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
